Neutralization of human papillomavirus by specific nanobodies against major capsid protein L1

Journal of Microbiology and Biotechnology

Volumn 22, Issue 5, 2012, Pages 721-728

  Minaeian, Sara ^a   Rahbarizadeh, Fatemeh ^b   Zarkesh Esfahani, Sayyed Hamid ^a   Ahmadvand, Davoud ^c   Broom, Oliver Jay ^d  

^a UNIVERSITY OF ISFAHAN   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KIPA Krahbichler Intellectual Property Advisors   (Sweden)

Author keywords

HPV 16; L1 protein; Nanobody; Phage display

Indexed keywords

CAPSID PROTEIN L1; CAPSID PROTEIN L1 NANOBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; WART VIRUS VACCINE;

ANTIBODY LIBRARY; ARTICLE; BACTERIOPHAGE; BIOPANNING; CONTROLLED STUDY; DRUG CROSS REACTIVITY; DRUG PROTEIN BINDING; DRUG PURIFICATION; DRUG SENSITIVITY; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE LIBRARY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOBLOTTING; NONHUMAN; PHAGE ENZYME LINKED IMMUNOSORBENT ASSAY; PHAGEMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; SENSITIVITY AND SPECIFICITY; VACCINATION; VIRUS NEUTRALIZATION;

ALPHAPAPILLOMAVIRUS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CELL LINE; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; SINGLE-CHAIN ANTIBODIES; SPECIES SPECIFICITY;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MIRIDAE;

EID: 84862069880     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: 10.4014/jmb.1112.12001     Document Type: Article

References (36)

1. Ahmadvand, D., M. J. Rasaee, F. Rahbarizadeh, R. E. Kontermann, and F. Sheikholislami. 2009. Cell selection and characterization of a novel human endothelial cell specific nanobody. Mol. Immunol. 46: 1814-1823.
2. Chen, X. S., R. L. Garcea, I. Goldberg, G. Casini, and S. C. Harrison. 2000. Structure of small virus-like particles assembled from the LI protein of human papillomavirus 16. Mol. Cell. 5: 557-567.
3. Christensen, N. D., J. W. Kreider, N. M. Cladel, S. D. Patrick, and P. A. Welsh. 1990. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J. Virol. 64: 5678-5681.
4. Christensen, N. D., C. A. Reed, N. M. Cladel, K. Hall, and G. S. Leiserowitz. 1996. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV 11 in addition to type-specific epitopes on HPV6. Virology 224: 477-486.
5. Culp, T. D. and N. D. Christensen. 2003. Quantitative RT-PCR assay for HPV infection in cultured cells. J. Virol. Methods 111: 135-144.
6. Culp, T. D., C. M. Spatz, C. A. Reed, and N. D. Christensen. 2007. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology 361: 435-446.
7. Day, P. M., C. D. Thompson, C. B. Buck, Y. Y. Pang, D. R. Lowy, and J. T. Schiller. 2007. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J. Virol. 81: 8784-8792.
8. Ganguly, N. and S. P. Parihar. 2009. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J. Biosci. 34: 113-123.
9. Hamers-Castennan, C., T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers, E. B. Songa, et al. 1993. Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
10. Harrison, J. L., S. C. Williams, G. Winter, and A. Nissim. 1996. Screening of phage antibody libraries. Methods Enzymol. 267: 83-109.
11. Holliger, P. and P. J. Hudson. 2005. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23: 1126-1136.
12. Kemp, T. J., A. Hildesheim, M. Safaeian, J. G. Dauner, Y. Pan, C. Porras, et al. 2011. HPV16/18 Ll VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29: 2011-2014.
13. Kirnbauer, R., F. Booy, N. Cheng, D. R. Lowy, and J. T. Schiller. 1992. Papillomavirus L1 major capsid protein selfassembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 89: 12180-12184.
14. Kimbauer, R., J. Taub, H. Greenstone, R. Roden, M. Durst, L. Gissmann, et al. 1993. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67: 6929-6936.
15. Klasse, P. J. and Q. J. Sattentau. 2001. Mechanisms of virus neutralization by antibody. Curr. Top. Microbiol. Immunol. 260: 87-108.
16. Laemmli, U. K. 1970. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227: 680-685.
17. Lin, K., K. Doolan, C. F. Hung, and T. C. Wu. 2010. Perspectives for preventive and therapeutic HPV vaccines. J. Formos. Med. Assoc. 109: 4-24.
18. Ludmerer, S. W., W. L. McClements, X. M. Wang, J. C. Ling, K. U. Jansen, and N. D. Christensen. 2000. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain. Virology 266: 237-245.
19. Modis, Y., B. L. Trus, and S. C. Harrison. 2002. Atomic model of the papillomavirus capsid. EMBO J. 21: 4754-4762.
20. Motoyama, S., C. A. Ladines-Llave, S. Luis Villanueva, and T. Maruo. 2004. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J. Med. Sci. 50: 9-19.
21. Muyldermans, S. 2001. Single domain camel antibodies: Current status. J. Biotechnol. 74: 277-302.
22. Parkin, D. M., M. Almonte, L. Bruni, G. Clifford, M. P. Curado, and M. Pineros. 2008. Burden and trends of type-specific human papillomavirus infections and related diseases in the Latin America and Caribbean region. Vaccine 26 (Suppl 11): L1-15.
23. Parkin, D. M., F. Bray, J. Ferlay, and P. Pisani. 2005. Global cancer statistics 2002. CA Cancer J. Clin. 55: 74-108.
24. Pastrana, D. V, C. B. Buck, Y. Y. Pang, C. D. Thompson, P. E. Castle, P. C. FitzGerald, et al. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321: 205-216.
25. Pathirana, D., P. Hillemanns, K. U. Petry, N. Becker, N. H. Brockmeyer, R. Erdmann, et al. 2009. Short version of the German evidence-based guidelines for prophylactic vaccination against HPVassociated neoplasia. Vaccine 27: 4551-4559.
26. Pomfret, T. C., J. M. Gagnon Jr., and A. T. Gilchrist. 2011. Quadrivalent human papillomavirus (HPV) vaccine: A review of safety, efficacy, and pharmacoeconomics. J. Clin. Pharm. Ther. 36: 1-9.
27. Rahbarizadeh, F., D. Ahmadvand, and Z. Sharifzadeh. 2011. Nanobody; an old concept and new vehicle for immunotargeting. Immunol. Invest. 40: 299-338.
28. Rahbarizadeh, F., M. J. Rasaee, M. Forouzandeh-Moghadam, and A. A. Allameh. 2005. High expression and purification of the recombinant camelid anti-MUC1 single domain antibodies in Escherichia coli. Protein Expr. Purif. 44: 32-38.
29. Rahbarizadeh, F., M. J. Rasaee, M. Forouzandeh, and A. A. Allameh. 2006. Over expression of anti-MUC 1 single-domain antibody fragments in the yeast Pichia pastoris. Mol. Immunol. 43: 426-435.
30. Rahbarizadeh, F., M. J. Rasaee, M. Forouzandeh Moghadam, A. A. Allameh, and E. Sadroddiny. 2004. Production of novel recombinant single-domain antibodies against tandem repeat region of MUC 1 mucin. Hybrid. Hybridomics 23: 151-159.
31. Rose, R. C., W. Bonnez, R. C. Reichman, and R. L. Garcea. 1993. Expression of human papillomavirus type 11 Ll protein in insect cells: In vivo and in vitro assembly of viruslike particles. J. Virol. 67: 1936-1944.
32. Sawaya, G.x F. 2009. Cervical-cancer screening - new guidelines and the balance between benefits and harms. N. Engl. J. Med. 361: 2503-2505.
33. Virgin, H. W., M. A. Mann, and K. L. Tyler. 1994. Protective antibodies inhibit reovirus internalization and uncoating by intracellular proteases. J. Virol. 68: 6719-6729.
34. White, W. I., S. D. Wilson, W. Bonnez, R. C. Rose, S. Koenig, and J. A. Suzich. 1998. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J. Virol. 72: 959-964.
35. Yang, T., L. Yang, W. Chai, R. Li, J. Xie, and B. Niu. 2011. A strategy for high-level expression of a single-chain variable fragment against TNFalpha by subcloning antibody variable regions from the phage display vector pCANTAB 5E into pBV220. Protein Expr Purif. 76: 109-114.
36. Zhuge, W., F. Jia, G Mackay, A. Kumar, and O. Narayan. 2001. Antibodies that neutralize SIV(mac)251 in T lymphocytes cause interruption of the viral life cycle in macrophages by preventing nuclear import of viral DNA. Virology 287: 436-445.